Search interest in glutathione in Miami has climbed steadily, and most of it lands on pages that answer a different question than the one patients are actually asking. People want to know whether to book an IV drip or a quick injection, whether one lasts longer, and whether either does what the marketing claims. Those are answerable questions — but only if you are willing to separate what has been measured in humans from what has been assumed.
This guide covers what glutathione is, what the published pharmacokinetic data actually show for intravenous versus intramuscular delivery, where U.S. regulation sits, the screening that genuinely matters before your first session, and how glutathione fits into a broader IV therapy plan. Some of what follows is less flattering to the category than a typical clinic page. We think that is the point.
Glutathione is a tripeptide made of glutamate, cysteine and glycine. It is the body's most abundant intracellular non-protein thiol and the workhorse of your endogenous antioxidant system — it neutralizes reactive oxygen species, supports phase II liver detoxification, and regenerates other antioxidants including vitamins C and E.
Two structural details explain everything that follows.
First, the bond at the glutamate end is a gamma-linkage, not a standard alpha peptide bond. That makes glutathione resistant to ordinary digestive peptidases, but it also means the molecule requires a specific enzyme — gamma-glutamyltransferase, or GGT — to be broken down and its components recycled. GGT is abundant in the intestine and liver.
Second, glutathione is overwhelmingly an intracellular molecule. Hepatocyte concentrations run in the millimolar range. Plasma concentrations run in the micromolar range — measured at roughly 6 to 18 micromoles per liter in healthy volunteers, a thousandfold difference. Circulating glutathione is a transport pool, not the functional pool. Raising the number in your blood is not automatically the same as raising the number inside your cells, and that distinction is where most glutathione marketing quietly falls apart.
Two well-conducted studies point in apparently opposite directions, and both are correct.
In 1992, Witschi and colleagues gave seven healthy volunteers a single large oral dose (about 3 grams) and measured plasma glutathione, cysteine and glutamate over 270 minutes. Nothing rose significantly. Their conclusion was blunt: systemic availability of oral glutathione is negligible in humans, because it is hydrolyzed by intestinal and hepatic GGT before it reaches the circulation intact.
In 2015, Richie and colleagues ran a six-month randomized, placebo-controlled trial in 54 non-smoking adults taking 250 mg or 1,000 mg of oral glutathione daily. At six months, the high-dose group showed roughly 30–35% increases in erythrocyte, plasma and lymphocyte glutathione, and a 260% increase in buccal cells. Values returned to baseline after a one-month washout.
The honest synthesis: a single oral dose does not measurably raise circulating glutathione; sustained daily oral dosing over months produces modest, reversible increases in body stores — possibly by supplying cysteine and other precursors rather than by absorbing the intact molecule. Anyone telling you oral glutathione is entirely useless is overstating Witschi. Anyone telling you a capsule matches an IV is overstating Richie.
Intravenous glutathione has the only good human pharmacokinetic dataset in this entire discussion, and it is worth knowing the numbers.
Aebi, Assereto and Lauterburg (1991) infused 2 g/m² of glutathione into ten healthy volunteers and measured what happened:
The authors' interpretation is the most useful sentence in the glutathione literature: parenteral glutathione appears to work largely as a cysteine delivery vehicle, not by directly loading cells with glutathione. Cysteine is the rate-limiting substrate your cells use to synthesize their own glutathione. That is a legitimate mechanism. It is simply not the mechanism most clinics describe.
Two practical implications. First, the enormous plasma spike is genuinely brief — this is not a molecule that sits in your bloodstream for days. Second, because clearance is dominated by the kidneys, renal function is a reasonable thing to know about before infusing large doses.
Here is the finding that should reframe your consultation: we could identify no published human pharmacokinetic study of intramuscular or subcutaneous glutathione. Not a small one, not an old one. Searches of the biomedical literature for glutathione plus intramuscular or subcutaneous plus pharmacokinetics return animal and tissue work only.
Human intramuscular glutathione has been used in andrology — Lenzi and colleagues published a 1992 open study and a 1993 placebo-controlled crossover trial using 600 mg IM every other day for two months in men with infertility, reporting improvements in sperm motility and morphology. Those trials measured clinical endpoints. They did not measure plasma levels.
So when a clinic tells you an intramuscular shot "lasts longer" or a subcutaneous injection gives "sustained levels," they are extrapolating from general depot-injection principles, not citing glutathione data. That extrapolation is not unreasonable — slower absorption from muscle or subcutaneous tissue genuinely does flatten the peak and extend the tail for many drugs. But it has not been demonstrated for this molecule, and no head-to-head comparison of IV push versus IV drip versus IM versus subcutaneous glutathione exists in the published human literature.
A clinic that tells you this plainly is more trustworthy than one that quotes you a duration.
Given the evidence above, the honest decision framework is less about pharmacokinetics and more about what you are trying to accomplish and what else is in the bag.
This is the most common and most defensible use. If you are already receiving an IV for hydration, B vitamins, magnesium and vitamin C, adding glutathione to that session is straightforward, requires no additional needle stick, and delivers a large short-lived antioxidant and cysteine load. In our Miami IV drip menu, glutathione appears in the antioxidant-oriented formulations rather than as a standalone product.
An intramuscular injection takes minutes rather than an hour and costs less per session, which makes a more frequent schedule practical. That is a real advantage — as long as you understand you are choosing it for logistics, not because a study showed superior kinetics.
This deserves a direct answer, because it is a substantial share of the demand. The clinical evidence for IV glutathione as a skin-lightening agent is close to nonexistent. A dermatology review found the evidence base limited to essentially a single study, which the reviewers criticized for its design and analysis. The better-quality pigmentation research used oral or topical glutathione, not intravenous:
Any effect is also reversible on discontinuation. And this is precisely the use case regulators have targeted — see the next section.
Glutathione genuinely participates in hepatic phase II conjugation, so the biochemistry is not invented. But "detox" as a marketing term implies removal of unspecified toxins in a way that produces a measurable clinical outcome, and there is no trial demonstrating that. If you have a specific exposure or a specific abnormal lab value, that is a medical problem with a medical workup. If you simply feel run down, the more useful conversation is about sleep, alcohol, training load and thyroid function.
There is no FDA-approved injectable glutathione product in the United States. Every injectable glutathione administered in a U.S. clinic is a compounded, unapproved drug. That is not automatically a problem — compounding is legal and often appropriate — but it means the quality of the compounding pharmacy is the quality of your treatment.
Glutathione currently sits in Category 1 on the FDA's 503A bulk drug substances nominations list (version updated May 2026), meaning the agency does not intend to take enforcement action against its use in patient-specific compounding while evaluation continues. It is worth knowing the history: at the June 2022 Pharmacy Compounding Advisory Committee meeting, FDA staff recommended against adding glutathione to the final 503A bulks list; the committee voted 8–5–1 in favor. That vote is non-binding, and a final rule has not been issued. Category 1 status is a holding position, not an endorsement.
Two FDA actions are directly relevant to patients:
The 2015 consumer update on injectable skin lightening. The FDA named glutathione among the ingredients in injectable skin-lightening and skin-bleaching products, described them as unapproved new drugs of unknown composition, and warned about contaminants, infection and disease transmission. The agency's stated position was that these products pose a potentially significant safety risk.
The 2019 compounding safety alert. The FDA warned compounders not to use a specific L-glutathione dietary supplement powder for sterile injectables after testing found excessive bacterial endotoxin — some results as high as five times the appropriate limit. Seven patients on a single day in January 2019 had immediate infusion reactions including nausea, vomiting, lightheadedness, chills and body aches; one developed hypotension and shortness of breath requiring hospitalization.
Outside the U.S., the Philippine FDA's 2019 advisory on glutathione for skin lightening is the most detailed regulatory document on the topic. It states there are no published guidelines for appropriate dosing or duration, and names liver, kidney and nervous system toxicity, Stevens-Johnson syndrome, kidney stone formation when combined with IV vitamin C in acidic urine, and hemolysis requiring hemodialysis in G6PD-deficient patients given high-dose vitamin C.
This is the single most important item on the list, and the reason is usually the vitamin C sitting next to the glutathione in the bag rather than the glutathione itself.
Glucose-6-phosphate dehydrogenase generates NADPH through the pentose phosphate pathway. Red blood cells have no alternative source of NADPH, and NADPH is exactly what is required to regenerate reduced glutathione via glutathione reductase. G6PD-deficient red cells therefore cannot buffer an oxidant load. The deficiency is common — roughly 10% of Black males in the United States, with elevated prevalence in people of African, Mediterranean, Middle Eastern and Southeast Asian ancestry, and around 400 million people worldwide.
A 2022 meta-summary in the Indian Journal of Critical Care Medicine reviewed 14 published cases of vitamin C-induced hemolysis from 1975 to 2020. The findings are sobering: 71% of cases had documented G6PD deficiency, 57% received vitamin C intravenously, only two of fourteen had any prior history of hemolysis — meaning most had no warning — and 79% developed hemolytic complications within three days. Half developed acute kidney injury, disseminated intravascular coagulation, oxalosis or methemoglobinemia. One patient died.
Two testing caveats worth knowing: G6PD assays can read falsely normal during or shortly after acute hemolysis, because the most deficient cells have already lysed. And heterozygous women can test normal due to X-inactivation mosaicism.
Glutathione clearance is dominated by renal excretion, and high-dose intravenous vitamin C is metabolized to oxalate, which has caused acute oxalate nephropathy in published case reports. A baseline creatinine and eGFR is reasonable, and a history of oxalate kidney stones is a genuine reason to modify a protocol.
A 2025 case report in the Journal of Burn Care & Research described a 33-year-old woman who developed Stevens-Johnson syndrome after IV glutathione with vitamin C and vitamin D. The authors specifically urged clinicians to ask patients presenting with SJS/TEN about wellness-center infusions.
A separate 2025 case report in Cureus described a woman who received a high-dose imported glutathione "revitalising" solution and, within an hour, collapsed with a systolic pressure of 50–60 mmHg, a temperature above 41°C, a white cell count of 26, markedly elevated procalcitonin, liver injury and coagulopathy. She required ICU admission and vasopressors and recovered in 48 hours. She had also been self-administering tirzepatide with markedly reduced food intake — a combination worth disclosing to any clinic before an infusion.
A 1997 randomized crossover study found that nebulized glutathione caused significant bronchoconstriction in mild asthmatics — FEV1 fell 19% — and the authors attributed it to sulfite formation. That study used the inhaled route, and it does not establish that intravenous glutathione causes bronchospasm. It does justify never nebulizing glutathione in an asthmatic and taking a careful sulfite-sensitivity history.
Separately, worth clearing up a common clinic error: sulfur is not sulfa. Glutathione contains a thiol group; it is not a sulfonamide. A sulfa antibiotic allergy is not a mechanistic contraindication to glutathione. There is also no published study addressing cross-reactivity, so the accurate statement is that no data exist — not that it is proven safe.
There are no adequate human safety data in pregnancy or lactation; the standard drug monographs advise avoiding use. If you are receiving chemotherapy, glutathione should be given only under your oncologist's direction. The concern that antioxidants might blunt chemotherapy is theoretical and unsettled — a 2002 randomized trial of glutathione before oxaliplatin found no reduction in tumor response rate — but this is not a decision for a wellness clinic to make independently.
Given the 2019 endotoxin alert and a documented 2015 cluster of seven endotoxin-poisoning cases in Sydney traced to a single compounding pharmacy, the most defensible safety question you can ask is simply: which pharmacy compounded this, is it a 503A or 503B facility, and can I see the sterility and endotoxin certificate of analysis?
A point that surprises most patients: glutathione is not part of the classical Myers' cocktail. The original formula, as used in the only published randomized trial of it, contains magnesium chloride, calcium gluconate, hydroxocobalamin, pyridoxine, dexpanthenol, B-complex, niacinamide and about 2,500 mg of vitamin C. Glutathione is a modern add-on.
That trial — a placebo-controlled study of intravenous micronutrient therapy in 34 fibromyalgia patients, weekly for eight weeks — found that both groups improved clinically meaningfully and that there were no statistically significant differences between the Myers' cocktail and placebo on any outcome. It remains the only published randomized trial of the formula. The defensible claim is that it is well tolerated and unproven against placebo.
None of this means an IV session is worthless. Rapid rehydration is real, correcting a documented deficiency is real, and the experience of an hour of enforced rest is not nothing. It means the claims should match the evidence. Our signature drip menu includes antioxidant-oriented formulations where glutathione is appropriate, and our team will tell you which components have evidence behind them and which are there for comfort.
For an immediate, large, short-lived rise in circulating glutathione and cysteine, IV is the only route with published human data. For convenience and cost per session, intramuscular is easier. No published head-to-head study compares them, so any clinic quoting you a duration for IM glutathione is extrapolating.
There is no evidence-based schedule, because no dose-ranging study has established one. Frequency in practice is driven by goals and budget. A clinic that ties frequency to a defined goal and a review date is being more honest than one that sells a standing weekly package.
Intravenous glutathione for skin lightening is not supported by credible evidence and has been the specific subject of FDA and international regulatory warnings. Modest effects have been shown for oral and topical forms in small trials, and those effects reverse when you stop.
It is commonly done, and it is the combination that makes G6PD screening important. High-dose IV vitamin C in a G6PD-deficient patient can cause serious hemolysis, and most people who experienced it had no prior warning.
Reported adverse events associated with injectable glutathione include infusion reactions, severe cutaneous reactions including Stevens-Johnson syndrome, and one reported case of reversible severe liver injury. The most common real-world harms in published clusters came from contaminated compounded product, which is why sourcing matters more than dose.
No. Injectable glutathione is an unapproved compounded drug used for wellness indications and is self-pay.
Nexsis BioHealth is a physician-led clinic at 40 SW 13th Street, Suite 601–602 in Brickell, serving Miami, Miami Beach, Coral Gables, Coconut Grove, Downtown Miami, Wynwood and Key Biscayne. If you want a straight answer about whether glutathione belongs in your plan — including the answer "probably not, here is what would help more" — that is the conversation we prefer to have.
Book a consultation or call (844) 741-1580. You can also review our full IV therapy menu or read about hyperbaric oxygen therapy and red light therapy.
This article is for general educational purposes and does not constitute medical advice, diagnosis or treatment, and it does not create a physician-patient relationship. Injectable glutathione is not approved by the U.S. Food and Drug Administration for any indication and is provided as a compounded preparation. Regulatory status changes; the information above reflects the position as of August 2026. Do not start, stop or change any therapy without consulting a licensed physician who has reviewed your medical history.
